Britain and America have reached a important trade agreement that will guarantee no tariffs on UK medicine exports being sold in the US market.
Key Provisions of the Accord
As part of the deal, the UK has agreed to raise expenditure on medicines through the public health system. This pledge ensures that duties on these key products will remain at nothing for a duration of the next three years.
This development follows recent warnings to significantly raise tariffs on branded drug imports, with potential rates mentioned as high as double the cost.
"This arrangement with the UK reinforces the international landscape for new treatments and introduces long-overdue fairness to transatlantic drug exports," a release declared.
Economic Significance
Medicines are one of the UK's largest goods shipped to the United States, which is clearly the primary buyer for leading UK drugmakers.
Statistics reveal that in the 12 months leading up to last September, the UK shipped pharmaceutical products valued at £11.1bn to the US. This value represented nearly one-fifth of total UK exports in that timeframe.
"This deal secures jobs, stimulates investment and sets the stage for the UK to emerge as a global hub for medical research," the Business and Trade Secretary remarked.
Key UK Commitments
The deal includes several key commitments from the UK:
- Price Threshold Increase: The UK will lift the cost ceiling at which it considers new medicines to be unaffordable by 25%.
- Higher Drug Budget: There is a target to increase overall NHS spending on medicines from 0.3% of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The sum pharmaceutical firms must pay back to the NHS to prevent overspending will be capped at 15%. Last year, refunds were more than 20%.
Broader Context
The pact takes place against a long-running tension between the sector and the British authorities over medicine costs and regulatory access.
These tensions were exacerbated by assertions that US consumers were charged a premium for the same drugs than people in the Britain and the EU.
Recently, several major drug company projects in the UK have been halted or abandoned, while major expansions have been directed toward American operations.
The Science Minister stated that the NHS must spend more on treatments, noting that its spending on drugs had decreased as a percentage of its overall budget over the previous ten-year period.
